
Richard G Wunderink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6476080/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases, 2007, 44, S27-S72.	2.9	5,203
2	Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. New England Journal of Medicine, 2015, 373, 415-427.	13.9	2,121
3	Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children. New England Journal of Medicine, 2015, 372, 835-845.	13.9	1,235
4	MERS, SARS and other coronaviruses as causes of pneumonia. Respirology, 2018, 23, 130-137.	1.3	795
5	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. European Respiratory Journal, 2017, 50, 1700582.	3.1	792
6	Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet, The, 1998, 351, 929-933.	6.3	670
7	Linezolid vs Vancomycin *. Chest, 2003, 124, 1789-1797.	0.4	590
8	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiâ€infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy, 2019, 39, 10-39.	1.2	545
9	Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature, 2021, 590, 635-641.	13.7	524
10	Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study. Clinical Infectious Diseases, 2012, 54, 621-629.	2.9	513
11	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infectious Diseases, The, 2021, 21, 226-240.	4.6	411
12	Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 932-939.	2.5	402
13	Ventilator-Associated Pneumonia Due to Pseudomonas Aeruginosa. Chest, 1996, 109, 1019-1029.	0.4	342
14	Monotherapy May Be Suboptimal for Severe Bacteremic Pneumococcal Pneumonia. Archives of Internal Medicine, 2001, 161, 1837.	4.3	342
15	Causes of Fever and Pulmonary Densities in Patients with Clinical Manifestations of Ventilator-Associated Pneumonia. Chest, 1994, 106, 221-235.	0.4	327
16	Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infectious Diseases and Therapy, 2018, 7, 439-455.	1.8	313
17	The Radiologic Diagnosis of Autopsyproven Ventilator-associated Pneumonia. Chest, 1992, 101, 458-463.	0.4	312
18	Highâ€Dose, Shortâ€Course Levofloxacin for Communityâ€Acquired Pneumonia: A New Treatment Paradigm. Clinical Infectious Diseases, 2003, 37, 752-760.	2.9	306

#	Article	IF	CITATIONS
19	Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Medicine, 2004, 30, 388-394.	3.9	301
20	Fibroproliferative Phase of ARDS. Chest, 1991, 100, 943-952.	0.4	292
21	High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia. American Journal of Emergency Medicine, 2013, 31, 401-405.	0.7	257
22	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infectious Diseases, The, 2021, 21, 213-225.	4.6	255
23	Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study*. Critical Care Medicine, 2005, 33, 952-961.	0.4	242
24	Community-Acquired Pneumonia. New England Journal of Medicine, 2014, 370, 543-551.	13.9	241
25	Pneumonia. Nature Reviews Disease Primers, 2021, 7, 25.	18.1	230
26	Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clinical Therapeutics, 2003, 25, 980-992.	1.1	227
27	Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study*. Critical Care Medicine, 2008, 36, 1089-1096.	0.4	225
28	Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni. Chest, 2003, 124, 91S.	0.4	218
29	Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infectious Diseases, The, 2019, 19, 1299-1311.	4.6	218
30	Aspiration pneumonia: A review of modern trends. Journal of Critical Care, 2015, 30, 40-48.	1.0	213
31	An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Critical Care, 2015, 19, 219.	2.5	209
32	PIRO score for community-acquired pneumonia: A new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia*. Critical Care Medicine, 2009, 37, 456-462.	0.4	194
33	Prompting Physicians to Address a Daily Checklist and Process of Care and Clinical Outcomes. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 680-686.	2.5	189
34	Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature, 2022, 602, 321-327.	13.7	179
35	Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. European Respiratory Journal, 2009, 33, 153-159.	3.1	176
36	Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia. Clinical Infectious Diseases, 2017, 65, 183-190.	2.9	175

#	Article	IF	CITATIONS
37	Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa*. Critical Care Medicine, 2014, 42, 2178-2187.	0.4	157
38	Association between surfactant protein B + 1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia*. Critical Care Medicine, 2004, 32, 1115-1119.	0.4	148
39	Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest, 2003, 124, 1789-97.	0.4	139
40	Preinfection Systemic Inflammatory Markers and Risk of Hospitalization Due to Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1440-1446.	2.5	136
41	Delayed Administration of Antibiotics and Atypical Presentation in Community-Acquired Pneumonia. Chest, 2006, 130, 11-15.	0.4	135
42	Advances in the causes and management of community acquired pneumonia in adults. BMJ: British Medical Journal, 2017, 358, j2471.	2.4	135
43	Analysis of National Trends in Admissions for Pulmonary Embolism. Chest, 2016, 150, 35-45.	0.4	133
44	<i>Staphylococcus aureus</i> Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clinical Infectious Diseases, 2016, 63, 300-309.	2.9	132
45	Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinician's viewpoint. American Journal of Medicine, 2001, 110, 41-48.	0.6	121
46	Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Medicine, 2020, 46, 943-953.	3.9	120
47	Medium-Term Survival after Hospitalization with Community-Acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 910-914.	2.5	119
48	Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Critical Care Medicine, 2003, 31, 718-728.	0.4	118
49	A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clinical Infectious Diseases, 2021, 73, e4539-e4548.	2.9	114
50	Being Overweight Is Associated With Greater Survival in ICU Patients. Critical Care Medicine, 2015, 43, 2623-2632.	0.4	113
51	Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 921-932.	2.5	108
52	The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clinical Infectious Diseases, 2020, 70, 1536-1545.	2.9	106
53	β2-Adrenergic agonists augment air pollution–induced IL-6 release and thrombosis. Journal of Clinical Investigation, 2014, 124, 2935-2946.	3.9	106
54	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. Chest, 2020, 158, 1896-1911.	0.4	105

#	Article	IF	CITATIONS
55	Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1561-1568.	2.5	104
56	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 2017, 43, 1187-1197.	3.9	103
57	Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Medicine, 2019, 45, 159-171.	3.9	100
58	A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 319-323.	1.3	97
59	Early Microbiological Response to Linezolid vs Vancomycin in Ventilator-Associated Pneumonia Due to Methicillin-Resistant Staphylococcus aureus. Chest, 2008, 134, 1200-1207.	0.4	96
60	Management of Bacterial Pneumonia in Ventilated Patients. Chest, 1992, 101, 500-508.	0.4	93
61	Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Critical Care Medicine, 2003, 31, 1367-1372.	0.4	92
62	Management of Community-acquired Pneumonia in Adults. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 157-164.	2.5	92
63	Low Tidal Volume Ventilation Use in Acute Respiratory Distress Syndrome*. Critical Care Medicine, 2016, 44, 1515-1522.	0.4	90
64	Community-Acquired Pneumonia Requiring Hospitalization. New England Journal of Medicine, 2015, 373, 2380-2382.	13.9	89
65	Predicting Severe Pneumonia Outcomes in Children. Pediatrics, 2016, 138, .	1.0	89
66	Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 46-53.	0.6	89
67	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infectious Diseases, The, 2020, 20, 330-340.	4.6	88
68	Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia. Clinical Infectious Diseases, 2018, 66, 1640-1641.	2.9	87
69	The Impact of Blood Cultures on Antibiotic Therapy in Pneumococcal Pneumonia. Chest, 1999, 116, 1278-1281.	0.4	81
70	Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. JAMA - Journal of the American Medical Association, 2015, 314, 1488.	3.8	81
71	Feasibility of Venovenous Extracorporeal Membrane Oxygenation Without Systemic Anticoagulation. Annals of Thoracic Surgery, 2020, 110, 1209-1215.	0.7	79
72	Etiology and Impact of Coinfections in Children Hospitalized With Community-Acquired Pneumonia. Journal of Infectious Diseases, 2018, 218, 179-188.	1.9	71

#	Article	IF	CITATIONS
73	Community-Acquired Pneumonia Visualized on CT Scans but Not Chest Radiographs. Chest, 2018, 153, 601-610.	0.4	71
74	Severe Respiratory Viral Infections. Infectious Disease Clinics of North America, 2017, 31, 455-474.	1.9	69
75	Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Critical Care, 2020, 24, 43.	2.5	69
76	Filgrastim in Patients With Pneumonia and Severe Sepsis or Septic Shock. Chest, 2001, 119, 523-529.	0.4	68
77	Potential Impact of Vancomycin Pulmonary Distribution on Treatment Outcomes in Patients with Methicillin-ResistantStaphylococcus aureusPneumonia. Pharmacotherapy, 2006, 26, 539-550.	1.2	68
78	A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome*. Critical Care Medicine, 2008, 36, 782-788.	0.4	68
79	Expanded Clinical Presentation of Community-Acquired Methicillin-Resistant Staphylococcus aureus Pneumonia. Chest, 2010, 138, 130-136.	0.4	65
80	Antibiotic Stewardship in the Intensive Care Unit. An Official American Thoracic Society Workshop Report in Collaboration with the AACN, CHEST, CDC, and SCCM. Annals of the American Thoracic Society, 2020, 17, 531-540.	1.5	63
81	Causes of Prolonged Mechanical Ventilation After Coronary Artery Bypass Surgery. Chest, 2002, 122, 245-252.	0.4	61
82	Clinical Criteria in the Diagnosis of Ventilator-Associated Pneumonia. Chest, 2000, 117, 191S-194S.	0.4	57
83	Health Care–Associated Infection (HAI): A Critical Appraisal of the Emerging Threat—Proceedings of the HAI Summit. Clinical Infectious Diseases, 2008, 47, S55-S99.	2.9	56
84	Influence of Antibiotics on the Detection of Bacteria by Culture-Based and Culture-Independent Diagnostic Tests in Patients Hospitalized With Community-Acquired Pneumonia. Open Forum Infectious Diseases, 2017, 4, ofx014.	0.4	56
85	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine, 2016, 88, 267-273.	1.4	54
86	Viral Pneumonia and Acute Respiratory Distress Syndrome. Clinics in Chest Medicine, 2017, 38, 113-125.	0.8	54
87	Future Research Directions in Pneumonia. NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 256-263.	2.5	54
88	Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. Vaccine, 2019, 37, 3352-3361.	1.7	54
89	Radiologic Diagnosis of Ventilator-Associated Pneumonia. Chest, 2000, 117, 188S-190S.	0.4	53
90	Principles and Practice of Antibiotic Stewardship in the ICU. Chest, 2019, 156, 163-171.	0.4	52

#	Article	IF	CITATIONS
91	Rapid Detection of Methicillin-Resistant Staphylococcus aureus in BAL. Chest, 2019, 155, 999-1007.	0.4	50
92	A Clinical Trial Comparing Physician Prompting With an Unprompted Automated Electronic Checklist to Reduce Empirical Antibiotic Utilization. Critical Care Medicine, 2013, 41, 2563-2569.	0.4	49
93	Multidimensional assessment of alveolar T cells in critically ill patients. JCI Insight, 2018, 3, .	2.3	49
94	Distinctive features of severe SARS-CoV-2 pneumonia. Journal of Clinical Investigation, 2021, 131, .	3.9	49
95	Dollars and sense in the intensive care unit: The costs of ventilator-associated pneumonia *. Critical Care Medicine, 2003, 31, 1582-1583.	0.4	48
96	Community-Acquired Pneumonia. New England Journal of Medicine, 2014, 370, 1861-1863.	13.9	48
97	Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?. Critical Care, 2015, 20, 19.	2.5	48
98	Bronchoalveolar Lavage Amylase Is Associated With Risk Factors for Aspiration and Predicts Bacterial Pneumonia*. Critical Care Medicine, 2013, 41, 765-773.	0.4	46
99	Association between timing of intubation and outcome in critically ill patients: A secondary analysis of the ICON audit. Journal of Critical Care, 2017, 42, 1-5.	1.0	46
100	Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays. Clinical Infectious Diseases, 2018, 66, 1504-1510.	2.9	46
101	The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. Chest, 2020, 158, 1008-1016.	0.4	46
102	The Effect of Rosuvastatin in a Murine Model of Influenza A Infection. PLoS ONE, 2012, 7, e35788.	1.1	46
103	Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States. Open Forum Infectious Diseases, 2015, 2, ofv106.	0.4	45
104	Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials. Open Forum Infectious Diseases, 2017, 4, ofx063.	0.4	44
105	Bronchoscopy on Intubated Patients with COVID-19 Is Associated with Low Infectious Risk to Operators. Annals of the American Thoracic Society, 2021, 18, 1243-1246.	1.5	44
106	VENTILATOR-ASSOCIATED PNEUMONIA. Clinics in Chest Medicine, 1995, 16, 173-193.	0.8	42
107	4G/5G Plasminogen Activator Inhibitor-1 Polymorphisms and Haplotypes Are Associated with Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1129-1137.	2.5	41
108	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. ERJ Open Research, 2018, 4, 00028-2018.	1.1	41

#	Article	IF	CITATIONS
109	A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine, 2019, 37, 5777-5787.	1.7	41
110	Airflow Limitation is Underrecognized in Well-Functioning Older People. Journal of the American Geriatrics Society, 2001, 49, 1032-1038.	1.3	40
111	Epidemiology and Long-term Clinical and Biologic Risk Factors for Pneumonia in Community-Dwelling Older Americans. Chest, 2013, 144, 1008-1017.	0.4	40
112	Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care. NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 511-523.	2.5	40
113	Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia. Chest, 2016, 150, 819-828.	0.4	38
114	A Critical Care Clinician Survey Comparing Attitudes and Perceived Barriers to Low Tidal Volume Ventilation with Actual Practice. Annals of the American Thoracic Society, 2017, 14, 1682-1689.	1.5	38
115	Serology Enhances Molecular Diagnosis of Respiratory Virus Infections Other than Influenza in Children and Adults Hospitalized with Community-Acquired Pneumonia. Journal of Clinical Microbiology, 2017, 55, 79-89.	1.8	38
116	Common chronic conditions do not affect performance of cell cycle arrest biomarkers for risk stratification of acute kidney injury. Nephrology Dialysis Transplantation, 2016, 31, 1633-1640.	0.4	35
117	Science review: Genetic variability in the systemic inflammatory response. Critical Care, 2002, 7, 308.	2.5	34
118	Genetic Susceptibility to Pneumonia. Clinics in Chest Medicine, 2005, 26, 29-38.	0.8	34
119	<i>Pseudomonas aeruginosa</i> Nosocomial Pneumonia: Impact of Pneumonia Classification. Infection Control and Hospital Epidemiology, 2015, 36, 1190-1197.	1.0	34
120	Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia. Current Infectious Disease Reports, 2018, 20, 3.	1.3	34
121	Prevalence, Risk Factors, and Outcomes of Bacteremic Pneumonia in Children. Pediatrics, 2019, 144, .	1.0	34
122	A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Critical Care, 2009, 13, R36.	2.5	33
123	Improved Detection of Respiratory Pathogens by Use of High-Quality Sputum with TaqMan Array Card Technology. Journal of Clinical Microbiology, 2017, 55, 110-121.	1.8	33
124	Staphylococcus aureus Pneumonia in the Community. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 470-479.	0.8	33
125	Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. Clinical Infectious Diseases, 2021, 73, 1216-1222.	2.9	33
126	Severe community-acquired pneumonia and PIRO: A new paradigm of management. Current Infectious Disease Reports, 2009, 11, 343-348.	1.3	32

#	Article	IF	CITATIONS
127	Adoption of a High-Impact Innovation in a Homogeneous Population. Physical Review X, 2014, 4, 041008.	2.8	32
128	Patient and Family Engagement During Treatment Decisions in an ICU: A Discourse Analysis of the Electronic Health Record*. Critical Care Medicine, 2019, 47, 784-791.	0.4	32
129	Multidimensional Assessment of the Host Response in Mechanically Ventilated Patients with Suspected Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1225-1237.	2.5	32
130	Multicenter Evaluation of the Unyvero Platform for Testing Bronchoalveolar Lavage Fluid. Journal of Clinical Microbiology, 2021, 59, .	1.8	32
131	Intracellular Adhesion Molecule Gly241Arg Polymorphism Has No Impact on ARDS or Septic Shock in Community-Acquired Pneumonia. Chest, 2002, 121, 85S-86S.	0.4	31
132	Trends in Pathogens Among Patients Hospitalized for Pneumonia From 1993 to 2011. JAMA Internal Medicine, 2014, 174, 1837.	2.6	31
133	Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with communityâ€acquired pneumonia. Respirology, 2020, 25, 543-551.	1.3	31
134	A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. Clinical Infectious Diseases, 2021, 73, e710-e718.	2.9	31
135	Genetics of sepsis and pneumonia. Current Opinion in Critical Care, 2003, 9, 384-389.	1.6	30
136	Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. Journal of Antimicrobial Chemotherapy, 2021, 76, 2902-2905.	1.3	30
137	Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infectious Disease Clinics of North America, 2004, 18, 743-759.	1.9	29
138	Comparative in vitro stimulation with lipopolysaccharide to study TNFα gene expression in fresh whole blood, fresh and frozen peripheral blood mononuclear cells. Journal of Immunological Methods, 2010, 357, 33-37.	0.6	29
139	Outcomes after extracorporeal membrane oxygenation support in COVIDâ€19 and nonâ€COVIDâ€19 patients. Artificial Organs, 2022, 46, 688-696.	1.0	29
140	Association of tumor necrosis factor gene polymorphisms and prolonged mechanical ventilation after coronary artery bypass surgery. Critical Care Medicine, 2003, 31, 133-140.	0.4	28
141	Nosocomial Pneumonia, Including Ventilator-associatedPneumonia. Proceedings of the American Thoracic Society, 2005, 2, 440-444.	3.5	28
142	Community-acquired Pneumonia versus Healthcare-associated Pneumonia. The Returning Pendulum. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 896-898.	2.5	28
143	In-Hospital Deaths Among Adults With Community-Acquired Pneumonia. Chest, 2018, 154, 628-635.	0.4	28
144	Adjunctive Therapy in Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 146-153.	0.8	27

#	Article	IF	CITATIONS
145	Empiric antibiotic, mechanical ventilation, and central venous catheter duration as potential factors mediating the effect of a checklist prompting intervention on mortality: an exploratory analysis. BMC Health Services Research, 2012, 12, 198.	0.9	27
146	The microbiome in mechanically ventilated patients. Current Opinion in Infectious Diseases, 2017, 30, 208-213.	1.3	27
147	Pneumococcal and Legionella Urinary Antigen Tests in Community-acquired Pneumonia: Prospective Evaluation of Indications for Testing. Clinical Infectious Diseases, 2019, 68, 2026-2033.	2.9	27
148	Comparing Nasopharyngeal and BAL SARS-CoV-2 Assays in Respiratory Failure. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 127-129.	2.5	27
149	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. Chest, 2020, 158, 1912-1918.	0.4	26
150	Adjunctive Therapy in Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 311-318.	0.8	25
151	How Important is Methicillin-Resistant Staphylococcus aureus as a Cause of Community-Acquired Pneumonia and What is Best Antimicrobial Therapy?. Infectious Disease Clinics of North America, 2013, 27, 177-188.	1.9	25
152	Statin Use and Hospital Length of Stay Among Adults Hospitalized With Community-acquired Pneumonia. Clinical Infectious Diseases, 2016, 62, 1471-1478.	2.9	25
153	Testing for Respiratory Viruses in Adults With Severe Lower Respiratory Infection. Chest, 2018, 154, 1213-1222.	0.4	25
154	A multiplex polymerase chain reaction assay for antibiotic stewardship in suspected pneumonia. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115179.	0.8	25
155	COVID-19: First Do No Harm. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1324-1325.	2.5	25
156	Early Prediction of Acute Kidney Injury in Critical Care Setting Using Clinical Notes and Structured Multivariate Physiological Measurements. Studies in Health Technology and Informatics, 2019, 264, 368-372.	0.2	25
157	Welkommen to Our World. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 426-427.	2.5	24
158	Relationship Between Body Mass Index and Outcomes Among Hospitalized Patients With Community-Acquired Pneumonia. Journal of Infectious Diseases, 2017, 215, 1873-1882.	1.9	24
159	Rhinovirus Viremia in Patients Hospitalized With Community-Acquired Pneumonia. Journal of Infectious Diseases, 2017, 216, 1104-1111.	1.9	24
160	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clinical Infectious Diseases, 2019, 69, 1912-1918.	2.9	24
161	Nucleic Acid–based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1070-1087.	2.5	23
162	Comparison of Clinical Prediction Models for Resistant Bacteria in Communityâ€onset Pneumonia. Academic Emergency Medicine, 2015, 22, 730-740.	0.8	22

#	Article	IF	CITATIONS
163	Severe pseudomonal infections. Current Opinion in Critical Care, 2006, 12, 458-463.	1.6	21
164	Antibiotic Resistance in Community-Acquired Pneumonia Pathogens. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 829-838.	0.8	21
165	Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial. Critical Care, 2021, 25, 290.	2.5	21
166	Tumor Necrosis Factor Gene Polymorphisms and the Variable Presentation and Outcome of Community-Acquired Pneumonia. Chest, 2002, 121, 87S.	0.4	20
167	Validity of Scoring Systems to Predict Risk of Prolonged Mechanical Ventilation After Coronary Artery Bypass Graft Surgery. Chest, 2002, 122, 239-244.	0.4	20
168	Corticosteroids for Severe Community-Acquired Pneumonia. JAMA - Journal of the American Medical Association, 2015, 313, 673.	3.8	20
169	Determinants of time to death in hospital in critically ill patients around the world. Intensive Care Medicine, 2016, 42, 1454-1460.	3.9	20
170	A Call for Rational Intensive Care in the Era of COVID-19. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 132-133.	1.4	20
171	Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes. Human Pathology, 2021, 113, 92-103.	1.1	20
172	Clinical relevance of angiotensin-converting enzyme gene polymorphisms to predict risk of mechanical ventilation after coronary artery bypass graft surgery*. Critical Care Medicine, 2004, 32, 922-927.	0.4	19
173	Identification of Bacterial and Viral Codetections With Mycoplasma pneumoniae Using the TaqMan Array Card in Patients Hospitalized With Community-Acquired Pneumonia. Open Forum Infectious Diseases, 2016, 3, ofw071.	0.4	19
174	Detection of respiratory pathogens in clinical samples using metagenomic shotgun sequencing. Journal of Medical Microbiology, 2019, 68, 996-1002.	0.7	19
175	Methicillin-ResistantS. aureusVentilator-Associated Pneumonia: Strategies to Prevent and Treat. Seminars in Respiratory and Critical Care Medicine, 2006, 27, 092-103.	0.8	18
176	Genetic variation in MYLK and lung injury in children and adults with community-acquired pneumonia*. Pediatric Critical Care Medicine, 2010, 11, 731-736.	0.2	18
177	Ventilator-Associated Tracheobronchitis. Chest, 2011, 139, 485-488.	0.4	18
178	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1513-1525.	1.3	18
179	Surrogate Markers and Microbiologic End Points. Clinical Infectious Diseases, 2010, 51, S126-S130.	2.9	17
180	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2021, 18, 1087-1097.	1.5	17

#	Article	IF	CITATIONS
181	Clinical trial design during and beyond the pandemic: the I-SPY COVID trial. Nature Medicine, 2022, 28, 9-11.	15.2	17
182	Proactive vs Reactive Machine Learning in Health Care. JAMA - Journal of the American Medical Association, 2022, 327, 623.	3.8	16
183	Linezolid and Vancomycin for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. Chest, 2004, 126, 315-316.	0.4	15
184	Decreasing Î ² -Lactam Resistance in Pneumococci From the Memphis Region*. Chest, 2003, 124, 519-525.	0.4	14
185	Genetics of Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 553-562.	0.8	14
186	Guidelines to Manage Community-Acquired Pneumonia. Clinics in Chest Medicine, 2018, 39, 723-731.	0.8	14
187	Parainfluenza Virus Types 1–3 Infections Among Children and Adults Hospitalized With Community-acquired Pneumonia. Clinical Infectious Diseases, 2020, 73, e4433-e4443.	2.9	14
188	Derivation of a Triage Algorithm for Chest Radiography of Community-acquired Pneumonia Patients in the Emergency Department. Academic Emergency Medicine, 2008, 15, 40-44.	0.8	13
189	The Role of MRSA in Healthcare-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 052-060.	0.8	13
190	Transcriptional Events during the Recovery from MRSA Lung Infection: A Mouse Pneumonia Model. PLoS ONE, 2013, 8, e70176.	1.1	13
191	POINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? Yes. Chest, 2017, 151, 737-739.	0.4	13
192	Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community Study. Open Forum Infectious Diseases, 2017, 4, ofx088.	0.4	13
193	Turning the Phage on Treatment of Antimicrobial-Resistant Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1081-1082.	2.5	13
194	Attributable Mortality of Ventilator-Associated Pneumonia. Sepsis, 1998, 1, 211-221.	0.5	12
195	Appropriate Microbiological Testing in Community-Acquired Pneumonia. Chest, 2001, 119, 5-7.	0.4	12
196	Respiratory infections: A current and future threat. Respirology, 2009, 14, 651-655.	1.3	12
197	Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes. Clinical Infectious Diseases, 2019, 69, 1218-1225.	2.9	12
198	CONTROVERSIES IN THE DIAGNOSIS OF VENTILATOR-ACQUIRED PNEUMONIA. Medical Clinics of North America, 2001, 85, 1565-1581.	1.1	11

#	Article	IF	CITATIONS
199	Healthcare-associated bacteremia: Stirring the mud*. Critical Care Medicine, 2006, 34, 2685-2686.	0.4	11
200	Reliability of the validated clinical diagnosis of pneumonia on validated outcomes after intracranial hemorrhage. Journal of Critical Care, 2012, 27, 527.e7-527.e11.	1.0	11
201	Rapid response team-triggered procalcitonin measurement predicts infectious intensive care unit transfers*. Critical Care Medicine, 2012, 40, 2090-2095.	0.4	10
202	A reliable and effective method of DNA isolation from old human blood paper cards. SpringerPlus, 2013, 2, 616.	1.2	9
203	Prompting physicians to address a daily checklist for antibiotics. Current Opinion in Critical Care, 2013, 19, 448-452.	1.6	9
204	In-Hospital Pneumococcal Polysaccharide Vaccination Is Associated With Detection of Pneumococcal Vaccine Serotypes in Adults Hospitalized for Community-Acquired Pneumonia. Open Forum Infectious Diseases, 2015, 2, ofv135.	0.4	9
205	High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis. European Respiratory Journal, 2017, 50, 1700013.	3.1	9
206	Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	9
207	Clinical Features of Human Metapneumovirus-Associated Community-acquired Pneumonia Hospitalizations. Clinical Infectious Diseases, 2021, 72, 108-117.	2.9	9
208	An 87-Year-Old Man With Hypotension and Confusion After Cystoscopy. Chest, 1999, 115, 1449-1451.	0.4	8
209	Prevention of Ventilator-Associated Pneumonia. Chest, 1999, 116, 1155-1156.	0.4	8
210	Pneumonia Complicating the Acute Respiratory Distress Syndrome. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 443-448.	0.8	8
211	A CAP on Antibiotic Duration. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 3-5.	2.5	8
212	Procalcitonin as a Biomarker in Rhinosinusitis: A Systematic Review. American Journal of Rhinology and Allergy, 2019, 33, 103-112.	1.0	8
213	Association between a rapid diagnostic test to detect methicillin-resistant <i>Staphylococcus Aureus</i> pneumonia and decreased vancomycin use in a medical intensive care unit over a 30-month period. Infection Control and Hospital Epidemiology, 2021, 42, 1385-1387.	1.0	8
214	miR-221-5p-Mediated Downregulation of JNK2 Aggravates Acute Lung Injury. Frontiers in Immunology, 2021, 12, 700933.	2.2	8
215	Methicillin-Resistant Staphylococcus aureus Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 304-309.	0.8	8

216 " â€~Tis a gift to be simple… ― Chest, 2003, 124, 777-778.

0.4 7

#	Article	IF	CITATIONS
217	Evaluation of ICU Admission Criteria and Diagnostic Methods for Patients With Severe Community-Acquired Pneumonia. Chest, 2008, 133, 828-829.	0.4	7
218	Influenza and bacterial pneumonia - constant companions. Critical Care, 2010, 14, 150.	2.5	7
219	Epidemic Viral Pneumonia and Other Emerging Pathogens. Clinics in Chest Medicine, 2011, 32, 451-467.	0.8	7
220	Lack of Association of the Caspase-12 Long Allele with Community-Acquired Pneumonia in People of African Descent. PLoS ONE, 2014, 9, e89194.	1.1	7
221	Impact of Multiple Daily Clinical Pharmacist-Enforced Assessments on Time in Target Sedation Range. Journal of Pharmacy Practice, 2018, 31, 445-449.	0.5	7
222	Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. Journal of Antimicrobial Chemotherapy, 2022, 77, 1166-1177.	1.3	7
223	A long and winding road *. Critical Care Medicine, 2004, 32, 1077-1079.	0.4	6
224	Ventilator-associated Complications, Ventilator-associated Pneumonia, and Newton's Third Law of Mechanics. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 882-883.	2.5	6
225	Bacterial Pneumonia and Lung Abscess. , 2016, , 557-582.e22.		6
226	Respiratory Viral and Atypical Pneumonias. Clinics in Chest Medicine, 2017, 38, xiii-xiv.	0.8	6
227	The Emperor's New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). Open Forum Infectious Diseases, 2017, 4, S30-S31.	0.4	6
228	A quantitative approach for the analysis of clinician recognition of acute respiratory distress syndrome using electronic health record data. PLoS ONE, 2019, 14, e0222826.	1.1	6
229	Community-Acquired Pneumonia: A Global Perspective. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 453-454.	0.8	6
230	Antibioticâ€resistant bacteria: <scp>COVID</scp> â€19 hasn't made the challenge go away. Respirology, 2021, 26, 1024-1026.	1.3	6
231	Linezolid Exerts Greater Bacterial Clearance but No Modification of Host Lung Gene Expression Profiling: A Mouse MRSA Pneumonia Model. PLoS ONE, 2013, 8, e67994.	1.1	6
232	Practical laboratory guidelines for performing respiratory cultures on patients with ventilator-associated pneumonia. Clinical Microbiology Newsletter, 1994, 16, 65-69.	0.4	5
233	Impact of Cytokine Gene Polymorphisms on Outcomes of Coronary Artery Bypass Graft Surgery. Chest, 2002, 121, 86S.	0.4	5
234	Update on Stenotrophomonas maltophilia Infection in the ICU. Clinical Pulmonary Medicine, 2007, 14, 17-22.	0.3	5

#	Article	IF	CITATIONS
235	ATS Core Curriculum 2014: Part I. Adult Pulmonary Medicine. Annals of the American Thoracic Society, 2014, 11, 1136-1144.	1.5	5
236	Intensive Care Unit Outcomes Among Patients With Cancer After Palliative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, 854-858.	0.4	5
237	Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2021, 65, e0041721.	1.4	5
238	Severe Community-Acquired Pneumonia. Chest, 2001, 120, 1053-1055.	0.4	4
239	Slow response times: Is it the pneumonia or the physician?*. Critical Care Medicine, 2005, 33, 1429-1430.	0.4	4
240	There Is No "Cap―on the Importance of Community-Acquired Pneumonia in the ICU. Chest, 2008, 133, 590-592.	0.4	4
241	Treatment of hospital-acquired pneumonia. Lancet Infectious Diseases, The, 2011, 11, 728.	4.6	4
242	Update in Sepsis and Pulmonary Infections 2013. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 25-31.	2.5	4
243	CAP death: what goes wrong when everything is right?. Lancet Infectious Diseases, The, 2015, 15, 995-996.	4.6	4
244	Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team. Clinical Infectious Diseases, 2016, 63, S39-S45.	2.9	4
245	Other Community Respiratory Viruses. Clinics in Chest Medicine, 2017, 38, 37-43.	0.8	4
246	Use of Multiple Imputation to Estimate the Proportion of Respiratory Virus Detections Among Patients Hospitalized With Community-Acquired Pneumonia. Open Forum Infectious Diseases, 2018, 5, ofy061.	0.4	4
247	First report of <i>Pseudomonas nitroreducens</i> cultured from the lungs of a patient with pneumonia. BMJ Case Reports, 2021, 14, e241327.	0.2	4
248	Ventilator-associated pneumonia: Lessons learned from clinical trials. Journal of Critical Care, 2008, 23, 2-4.	1.0	3
249	Guideline Tyranny: A Response to the Article by Baum and Kaltsas. Clinical Infectious Diseases, 2008, 47, 1117-1118.	2.9	3
250	Another Piece of the Community-Acquired Pneumonia Puzzle. Chest, 2008, 134, 1112-1114.	0.4	3
251	Update in Pulmonary Infections 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 186-190.	2.5	3
252	Pulmonary hospitalizations and ischemic heart disease events in patients with peripheral artery disease. Vascular Medicine, 2017, 22, 218-224.	0.8	3

#	Article	IF	CITATIONS
253	Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired Pneumonia. Open Forum Infectious Diseases, 2017, 4, ofw254.	0.4	3
254	Pyogenic Bacterial Pneumonia and Lung Abscess. , 2010, , 699-740.		3
255	Severe community-acquired pneumonia: The search for the diagnostic holy grail continues*. Critical Care Medicine, 2011, 39, 2354-2355.	0.4	2
256	Update in Respiratory Infections 2011. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1261-1265.	2.5	2
257	What is Pneumonia?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, P1-P2.	2.5	2
258	A Simple Microsoft Excel Method to Predict Antibiotic Outbreaks and Underutilization. Infection Control and Hospital Epidemiology, 2017, 38, 860-862.	1.0	2
259	Serological response to influenza vaccination among adults hospitalized with communityâ€acquired pneumonia. Influenza and Other Respiratory Viruses, 2019, 13, 208-212.	1.5	2
260	2841. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate (TZD) and Linezolid (LZD) for Treatment of Ventilated Gram-Positive (G+) Nosocomial Pneumonia. Open Forum Infectious Diseases, 2019, 6, S67-S67.	0.4	2
261	Genetic Effects on Sepsis and Pneumonia. Clinical Pulmonary Medicine, 2004, 11, 143-153.	0.3	1
262	Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease. Current Opinion in Critical Care, 2006, 12, 420-425.	1.6	1
263	Conflicting roles of Fcl ³ Rlla H131R polymorphism in pneumonia*. Critical Care Medicine, 2011, 39, 1577-1579.	0.4	1
264	Response. Chest, 2018, 153, 763-764.	0.4	1
265	Reply to Chao and Lai. Clinical Infectious Diseases, 2021, 73, 1552-1553.	2.9	1
266	Decreasing incidence of <i>Acinetobacter baumannii</i> pneumonia and trends in antibiotic consumption: A single-center retrospective observational study. Infection Control and Hospital Epidemiology, 2022, 43, 1155-1161.	1.0	1
267	Clinical impact of bacterial syndromic testing in pneumonia. Lancet Respiratory Medicine,the, 2022, , .	5.2	1
268	Scenario 2: Communityâ€Acquired Pneumonia Requiring Hospitalization but Not Requiring Admission to an Intensive Care Unit. Clinical Infectious Diseases, 2008, 47, S186-S188.	2.9	0
269	Gene expression profiling in acute respiratory distress syndrome: Pathways to future interventions*. Critical Care Medicine, 2008, 36, 1014-1015.	0.4	0

Adjunctive Therapy in Community-Acquired Pneumonia. , 0, , 245-262.

0

#	Article	IF	CITATIONS
271	The Value of Procalcitonin in CAP Remains Unclear. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1210-1211.	2.5	0
272	Reply to Chalmers et al. Clinical Infectious Diseases, 2016, 63, 1146-1147.	2.9	0
273	Rebuttal From Dr Wunderink. Chest, 2017, 151, 743-744.	0.4	0
274	209. Impact of a Risk-based CAP Prescribing Guideline Paired with Antimicrobial Stewardship to Improve Antibiotic Prescribing for Patients at Low Risk for Drug-Resistant Pathogens. Open Forum Infectious Diseases, 2018, 5, S91-S91.	0.4	0
275	2203. Patient-Specific Risk Stratification to Identify Patients at High and Low Risk for P. aeruginosa in Community-Acquired Pneumonia. Open Forum Infectious Diseases, 2019, 6, S751-S751.	0.4	0
276	Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia – Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 20-21.	4.6	0
277	Empiric Carbapenems for Nosocomial Pneumonia. Chest, 2021, 159, 897-899.	0.4	0
278	Hospital-Acquired Pneumonia Caused by Pseudomonas Aeruginosa. Perspectives on Critical Care Infectious Diseases, 2003, , 37-54.	0.1	0
279	Why Do Some Patients Get Severe Pneumonia?. Lung Biology in Health and Disease, 2005, , 25-38.	0.1	0
280	Macrolides in Severe Community-Acquired Pneumonia and Sepsis. , 2008, , 1-17.		0
281	Methodology for Clinical Investigation of Ventilator-Associated Pneumonia: Epidemiology and Therapeutic Intervention. Infection Control and Hospital Epidemiology, 1992, 13, 667-677.	1.0	0
282	Community Acquired Pneumonia. , 2020, , 155-160.		0
283	1490. Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant <i>Acinetobacter baumannii-calcoaceticus</i> Complex - A Retrospective Review. Open Forum Infectious Diseases, 2020, 7, S747-S747.	0.4	0
284	803. Risk factors associated with <i>Clostridioides difficile</i> infection in hospitalized patients with community-acquired pneumonia. Open Forum Infectious Diseases, 2020, 7, S445-S445.	0.4	0
285	Title is missing!. , 2019, 14, e0222826.		0
286	Title is missing!. , 2019, 14, e0222826.		0
287	Title is missing!. , 2019, 14, e0222826.		0

#	Article	IF	CITATIONS
289	Assessment of Patients with Poor Resolution of Hospital-Acquired Pneumonia. , 0, , 245-256.		0